Entering text into the input field will update the search result below

Athersys expands collaboration with Healios; shares ahead 16% premarket

  • Athersys (NASDAQ:ATHX) has entered into an agreement with HEALIOS K.K. to expand their collaboration into additional therapeutic areas.
  • Healios receives rights to develop and commercialize additional indications and Athersys receives $20M in license fees, milestones payments of up to ~$360M as well as tiered double-digit royalties on MultiStem therapies developed for ARDS, and single-digit royalties for other licensed products.
  • Under the terms of the agreement, Healios will also receive a credit of $10M and a right of first negotiation to broaden the field and territory related to MultiStem cells used in combination with iPSC-derived cells. It has been granted a right of first negotiation regarding an exclusive option for a license to develop and commercialize MultiStem therapy for certain indications in China, and the potential inclusion of an additional indication to the Japan license.
  • Shares of ATHX are up 16% premarket on modest volume.
  • Previously: Healios and Athersys expand MultiStem partnership (March 13)

Recommended For You

About ATHXQ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ATHXQ--
Athersys, Inc.